Engineered adenovirus serotypes for overcoming anti-vector immunity

Bibliography

• Wold WSM, Tollefson AE. Adenovirus methods and protocols adenoviruses, ad vectors, quantitation, and animal models. 2nd edition. Humana Press, Totowa, New Jersey; 2007
   Google Scholar
• Hierholzer JC, Wigand R, Anderson LJ, et al. Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types 43-47). J Infect Dis 1988;158:804-13
   PubMed Web of Science ®Google Scholar
• Schnurr D, Dondero ME. Two new candidate adenovirus serotypes. Intervirology 1993;36:79-83
   PubMed Web of Science ®Google Scholar
• De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, et al. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 1999;37:3940-5
   PubMed Web of Science ®Google Scholar
• Hong SS, Karayan L, Tournier J, et al. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 1997;16:2294-306
   PubMed Web of Science ®Google Scholar
• Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000;268:382-90
   PubMed Web of Science ®Google Scholar
• Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994;5:1217-29
   PubMed Web of Science ®Google Scholar
• Ghadge GD, Roos RP, Kang UJ, et al. CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Ther 1995;2:132-7
   PubMed Web of Science ®Google Scholar
• Horellou P, Vigne E, Castel MN, et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 1994;6:49-53
   PubMed Web of Science ®Google Scholar
• Straus SE. Adenovirus infections in humans. In: The Adenoviruses, Ginsberg HS, Editor, Plenus Press, New York; 1984. p. 451-96
   Google Scholar
• Horwitz MS. Adenoviridae and their replication. In: Virology, Fields BN and Knipe DM, Editors, Raven Press, New York; 1990. p. 1679-721
   Google Scholar
• Jager L, Ehrhardt A. Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther 2007;7:272-83
   PubMed Web of Science ®Google Scholar
• Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-11
   PubMed Web of Science ®Google Scholar
• Yang Y, Nunes FA, Berencsi K, et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362-9
   PubMed Web of Science ®Google Scholar
• Zabner J, Petersen DM, Puga AP, et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994;6:75-83
   PubMed Web of Science ®Google Scholar
• Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51
   PubMed Web of Science ®Google Scholar
• Palmer DJ, Ng P. Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther 2005;16:1-16
   PubMed Web of Science ®Google Scholar
• Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998;95:7866-71
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N, Ng T, Iannitti DA, et al. Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther 2006;17:391-404
   PubMed Web of Science ®Google Scholar
• Koehler DR, Frndova H, Leung K, et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med 2005;7:1409-20
   PubMed Web of Science ®Google Scholar
• Koehler DR, Martin B, Corey M, et al. Readministration of helper-dependent adenovirus to mouse lung. Gene Ther 2006;13:773-80
   PubMed Web of Science ®Google Scholar
• Amalfitano A, Parks RJ. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther 2002;2:111-33
   PubMedGoogle Scholar
• Flotte TR, Ng P, Dylla DE, et al. Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther 2007;15:229-41
   PubMed Web of Science ®Google Scholar
• Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther 2003;8:846-52
   PubMed Web of Science ®Google Scholar
• Chirmule N, Hughes JV, Gao GP, et al. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 1998;72:6138-45
   PubMed Web of Science ®Google Scholar
• Chirmule N, Truneh A, Haecker SE, et al. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. J Immunol 1999;163:448-55
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58
   PubMed Web of Science ®Google Scholar
• Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008;132:1-14
   PubMed Web of Science ®Google Scholar
• He Z, Wlazlo AP, Kowalczyk DW, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000;270:146-61
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996;219:220-7
   PubMed Web of Science ®Google Scholar
• Tims T, Briggs DJ, Davis RD, et al. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine 2000;18:2804-7
   PubMed Web of Science ®Google Scholar
• Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006;312:1530-3
   PubMed Web of Science ®Google Scholar
• Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424:681-4
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Mennuni C, Giannetti P, et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 2007;120:2290-300
   PubMed Web of Science ®Google Scholar
• Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008;46:1769-81
   PubMed Web of Science ®Google Scholar
• Cox KS, Clair JH, Prokop MT, et al. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol 2008;82:8161-71
   PubMed Web of Science ®Google Scholar
• Mastrangeli A, Harvey BG, Yao J, et al. ‘Sero-switch’ adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996;7:79-87
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305-13
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Gao GP, Reyes-Sandoval A, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003;170:1416-22
   PubMed Web of Science ®Google Scholar
• Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006;441:239-43
   PubMed Web of Science ®Google Scholar
• Kresge KJ. Renewed promise. Annual AIDS vaccine meeting highlights recent data from clinical trials and lessons on recruitment and retention of volunteers. IAVI Rep 2005;9:18-20
   PubMedGoogle Scholar
• Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008;205:7-12
   PubMed Web of Science ®Google Scholar
• Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998;9:1909-17
   PubMed Web of Science ®Google Scholar
• Guibinga GH, Lochmuller H, Massie B, et al. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J Virol 1998;72:4601-9
   PubMed Web of Science ®Google Scholar
• Ye X, Robinson MB, Pabin C, et al. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Ther 2000;7:1761-7
   PubMed Web of Science ®Google Scholar
• Singh R, Tian B, Kostarelos K. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. Faseb J 2008;22:3389-402
   PubMed Web of Science ®Google Scholar
• Sakurai F, Kawabata K, Mizuguchi H. Adenovirus vectors composed of subgroup B adenoviruses. Curr Gene Ther 2007;7:229-38
   PubMed Web of Science ®Google Scholar
• Fattori E, Zampaglione I, Arcuri M, et al. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther 2006;13:1088-96
   PubMed Web of Science ®Google Scholar
• Douglas JT, Miller CR, Kim M, et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 1999;17:470-5
   PubMed Web of Science ®Google Scholar
• Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002;76:8621-31
   PubMed Web of Science ®Google Scholar
• Sarkioja M, Pesonen S, Raki M, et al. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther 2008;15:921-9
   PubMed Web of Science ®Google Scholar
• Sailaja G, HogenEsch H, North A, et al. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther 2002;9:1722-9
   PubMed Web of Science ®Google Scholar
• Roy S, Shirley PS, McClelland A, Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 1998;72:6875-9
   PubMed Web of Science ®Google Scholar
• Crawford-Miksza L, Schnurr DP. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 1996;70:1836-44
   PubMed Web of Science ®Google Scholar
• Arnberg N, Edlund K, Kidd AH, Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000;74:42-8
   PubMed Web of Science ®Google Scholar
• Short JJ, Pereboev AV, Kawakami Y, et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004;322:349-59
   PubMed Web of Science ®Google Scholar
• Barouch DH, Pau MG, Custers JH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004;172:6290-7
   PubMed Web of Science ®Google Scholar
• Lemckert AA, Sumida SM, Holterman L, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005;79:9694-701
   PubMed Web of Science ®Google Scholar
• Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004;55:355-72
   PubMed Web of Science ®Google Scholar
• Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006;24:849-62
   PubMed Web of Science ®Google Scholar
• Wuest T, Both GW, Prince AM, et al. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 2004;22:2717-21
   PubMed Web of Science ®Google Scholar
• McCoy K, Tatsis N, Korioth-Schmitz B, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007;81:6594-604
   PubMed Web of Science ®Google Scholar
• Tatsis N, Tesema L, Robinson ER, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 2006;13:421-9
   PubMed Web of Science ®Google Scholar
• Zhi Y, Figueredo J, Kobinger GP, et al. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 2006;17:500-6
   PubMed Web of Science ®Google Scholar
• Zhou D, Cun A, Li Y, et al. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther 2006;14:662-72
   PubMed Web of Science ®Google Scholar
• Peruzzi D, Dharmapuri S, Cirillo A, et al. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009;27:1293-300
   PubMed Web of Science ®Google Scholar
• Perreau M, Mennechet F, Serratrice N, et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol 2007;81:3272-84
   PubMed Web of Science ®Google Scholar
• Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 2005;79:14595-605
   PubMed Web of Science ®Google Scholar
• Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res 2004;105:127-36
   PubMed Web of Science ®Google Scholar
• Renaut L, Colin M, Leite JP, et al. Abolition of hCAR-dependent cell tropism using fiber knobs of Atadenovirus serotypes. Virology 2004;321:189-204
   PubMed Web of Science ®Google Scholar
• Bangari DS, Shukla S, Mittal SK. Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 2005;327:960-6
   PubMed Web of Science ®Google Scholar
• Bangari DS, Mittal SK. Porcine adenovirus serotype 3 internalization is independent of CAR and alphavbeta3 or alphavbeta5 integrin. Virology 2005;332:157-66
   PubMed Web of Science ®Google Scholar
• Bangari DS, Sharma A, Mittal SK. Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun 2005;331:1478-84
   PubMed Web of Science ®Google Scholar
• Sharma A, Bangari DS, Tandon M, et al. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009;386:44-54
   PubMed Web of Science ®Google Scholar
• Roy S, Kobinger GP, Lin J, et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007;25:6845-51
   PubMed Web of Science ®Google Scholar
• Ryan SO, Gantt KR, Finn OJ. Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol 2007;142:179-89
   PubMed Web of Science ®Google Scholar
• Facciabene A, Aurisicchio L, Elia L, et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 2006;17:81-92
   PubMed Web of Science ®Google Scholar
• Facciabene A, Aurisicchio L, Elia L, et al. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 2007;26:47-58
   PubMed Web of Science ®Google Scholar
• Gallo P, Dharmapuri S, Nuzzo M, et al. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int J Cancer 2007;120:574-84
   PubMed Web of Science ®Google Scholar
• Mennuni C, Calvaruso F, Facciabene A, et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005;117(3):444-55
   PubMed Web of Science ®Google Scholar
• De Geest B, Snoeys J, Van Linthout S, et al. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum Gene Ther 2005;16:1439-51
   PubMed Web of Science ®Google Scholar
• Koizumi N, Kawabata K, Sakurai F, et al. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 2006;17:264-79
   PubMed Web of Science ®Google Scholar
• Koizumi N, Yamaguchi T, Kawabata K, et al. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 2007;178:1767-73
   PubMed Web of Science ®Google Scholar
• Sakurai H, Kawabata K, Sakurai F, et al. Innate immune response induced by gene delivery vectors. Int J Pharm 2008;354:9-15
   PubMed Web of Science ®Google Scholar
• Liu Q, Zaiss AK, Colarusso P, et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003;14:627-43
   PubMed Web of Science ®Google Scholar
• Tamanini A, Nicolis E, Bonizzato A, et al. Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells. J Virol 2006;80:11241-54
   PubMed Web of Science ®Google Scholar
• Schoggins JW, Nociari M, Philpott N, Falck-Pedersen E. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. J Virol 2005;79:11627-37
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004;78:5368-81
   PubMed Web of Science ®Google Scholar
• Mizuguchi H, Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther 2004;15:1034-44
   PubMed Web of Science ®Google Scholar
• Osada T, Yang XY, Hartman ZC, et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Therapy 2009 [Epub ahead of print; doi: 10.1038/cgt.2009.17]
   PubMedGoogle Scholar
• Shirakawa T. Clinical trial design for adenoviral gene therapy products. Drug News Perspect 2009;22:140-5
   PubMed Web of Science ®Google Scholar
• Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17
   PubMedGoogle Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar